Other Information.
−Removed: On January 10, 2024 , David M.
−Removed: Chacko , M.D., our Chief Financial Officer and Chief Business Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 260,000 shares of our common stock until December 31, 2025 .
−Removed: During the three months ended March 31, 2024 , no other officers (as defined in Rule 16a–1(f)) or directors adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each such term is defined in Item 408 of Regulation S-K.
+Added: On June 30, 2024 , each of Shannon Morris , M.D., Ph.D., our Chief Medical Officer , and Ebun Garner , J.D., our General Counsel , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 80,000 and 200,000 shares of our common stock until March 31, 2026 and June 30, 2026 , respectively .
+Added: During the three months ended June 30, 2024 , no other officers (as defined in Rule 16a–1(f)) or directors adopted , materially modified or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each such term is defined in Item 408 of Regulation S-K.
Exhibit Description
5 unchanged sentences
Amended and Restated Stockholders Agreement, dated April 15, 2020, by and among the Registrant and certain of its stockholders
−Removed: Stock Purchase Agreement, dated March 27, 2024, by and between Erasca, Inc.
−Removed: and each of the purchasers party thereto
+Added: License Agreement, dated May 15, 2024, by and between Guangzhou Joyo Pharmatech Co., Ltd., and Erasca, Inc.
+Added: License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc.
Certification of Chief Executive Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
5 unchanged sentences
Cover Page Interactive Data File (embedded within the Inline XBRL document)
+Added: Portions of this exhibit have been omitted for confidentiality purposes.
* This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 12, 2024
/s/ Jonathan E.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 12, 2024
Chief Financial Officer and Chief Business Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.